2020 Sees Sharp Rise In EU New Drug Approvals
Products Include COVID-19 Vaccine & Remdesivir, Plus Three Gene Therapies
Executive Summary
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.
You may also be interested in...
EU Launches ‘Structured Dialog’ To Thrash Out Supply Chain Concerns
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
And The UK's First 'Innovation Passport' Goes To... MSD's Rare Disease Drug Belzutifan
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up
A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: